Neurocrine Biosciences, Inc. ( NBIX) Discusses Progress and Strategy in Neurology and Obesity R&D Programs December 16, 2025 12:00 PM EST ...
The FDA is expected to decide on treatments for breast cancer, EBV+ post-transplant lymphoproliferative disease, focal segmental glomerulosclerosis, presbyopia, and severe allergic reactions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results